Sprouty 2: a novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL
- 12 May 2016
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 127 (19) , 2310-2321
Abstract
Key Points: SPRY2 is downregulated in CLL cells from patients with poor prognosis. SPRY2 is negative regulator of Syk-mediated BCR and MAPK-Erk signaling in CLL.Keywords
This publication has 43 references indexed in Scilit:
- Accelerated Development of Chronic Lymphocytic Leukemia in New Zealand Black Mice Expressing a Low Level of Interferon Regulatory Factor 4Journal of Biological Chemistry, 2013
- SPRY2 loss enhances ErbB trafficking and PI3K/AKT signalling to drive human and mouse prostate carcinogenesisEMBO Molecular Medicine, 2012
- The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemiaBlood, 2011
- Modulation of K-Ras-Dependent Lung Tumorigenesis by MicroRNA-21Cancer Cell, 2010
- The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective mannerProceedings of the National Academy of Sciences, 2010
- Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemiaProceedings of the National Academy of Sciences, 2009
- Cell–cell contact globally activates microRNA biogenesisProceedings of the National Academy of Sciences, 2009
- Expression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomasBlood, 2009
- Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinomaJournal of Clinical Investigation, 2007
- Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesisGenes & Development, 2007